Trial Profile
A Phase 1/2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Feb 2019
Price :
$35
*
At a glance
- Drugs MIS 416 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Amplia Therapeutics Limited; Innate Immunotherapeutics
- 28 Apr 2017 Results (n=102) assessing effect of mutations in the gene NFKBIA on patients response to MIS416 using patient data from NCT02228213 and NCT01191996 trials, presented at the 69th Annual Meeting of the American Academy of Neurology
- 28 Apr 2017 Results of profiling the kynurenine pathway and effect of MIS416 on Kynurenine pathway, presented at the 69th Annual Meeting of the American Academy of Neurology
- 28 Apr 2017 Results (n=11) assessing neurological status of SPMS patients, presented at the 69th Annual Meeting of the American Academy of Neurology